RBC keeps EUR 220 target for Sartorius stock

Published on 10/09/2026 at 11:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius stock stood at EUR 251.95 on October 9, 2026, below its EUR 271.90 high. Fiscal 2026 guidance is 5 to 9 percent growth.

Key points in brief

RBC kept a Sector Perform rating and EUR 220.00 target for Sartorius on October 6, 2026.
Goldman Sachs raised its target from EUR 228.00 to EUR 244.00 on October 1, 2026.
Sartorius guided for fiscal 2026 revenue growth of 5 to 9 percent and an underlying EBITDA margin above 30 percent.
The stock was trading at EUR 251.95 at Lang & Schwarz on October 9, 2026, up 1.33 percent from the prior close.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius (ISIN DE0007165631) was trading at EUR 251.95 at Lang & Schwarz on October 9, 2026 at 11:02 a.m. CEST, up 1.33 percent from the prior close. On October 6, 2026, RBC kept a Sector Perform rating and a EUR 220.00 target, citing limited effects from tariff refunds, the MATTEK acquisition and currency movements, according to FinanzNachrichten.

Recent targets point in different directions

On September 30, 2026, Barclays raised its Sartorius target from EUR 300.00 to EUR 310.00 and retained Overweight, according to finanzen.ch. On October 1, 2026, Goldman Sachs lifted its target from EUR 228.00 to EUR 244.00 while keeping Neutral, as reported by finanzen.at.

What does the 5 to 9 percent outlook mean?

Sartorius management expects fiscal 2026 sales revenue growth of 5 to 9 percent in constant currencies and an underlying EBITDA margin above 30 percent, compared with 29.70 percent in fiscal 2025, according to the company investor-relations page. The outlook includes a contribution from MATTEK and tariff-related effects, while the Lab Products and Services division carries a lower margin profile than Bioprocess Solutions. The comparison matters because the margin target implies expansion even while the group is guiding to a broad revenue range.

Three recent events with figures

On September 30, 2026, Barclays moved its target from EUR 300.00 to EUR 310.00. On October 1, 2026, Goldman Sachs moved its target from EUR 228.00 to EUR 244.00. On October 6, 2026, RBC maintained EUR 220.00 and Sector Perform. Each step was linked to a different reading of the recovery in bioprocessing, expected quarterly performance or the effects of MATTEK and tariffs.

Next report date is October 22

The next dated event is October 22, 2026, when Sartorius is scheduled to publish its nine-month results and hold a conference call at 1:00 p.m. CEST, according to Sartorius. The company is listed on Xetra and is a member of the MDAX, giving the October report a clear near-term reference point for the competing analyst targets.

Stock trades above EUR 250

Sartorius was trading at EUR 251.95 at Lang & Schwarz on October 9, 2026 at 11:02 a.m. CEST, versus a prior close of EUR 248.65 and a plus 1.33 percent daily change. The same-day primary-listing quote was EUR 252.00 in euros, while the 52-week range was EUR 198.50 to EUR 271.90 and market capitalization was EUR 17.4 billion as of October 9, 2026 at 10:47 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.